Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: A pilot open-label trial

Keyphrases

• Abnormal Involuntary Movement Scale 12%
• Akathisia 12%
• Antipsychotics 100%
• Beneficial Effects 12%
• Bexarotene 100%
• Change from Baseline 12%
• Cholesterol 25%
• Chronic Schizophrenia 25%
• Complete Blood Count 12%
• Counting Function 12%
• Dermatological Diseases 12%
• Dysphoric Mood 12%
• Dysregulation 12%
• Extrapyramidal Symptoms 25%
• Factor Scores 12%
• General Psychopathology 12%
• Laboratory Parameters 12%
• Liver Function 12%
• Mental Condition 12%
• Mental Hospital 12%
• Negative Symptoms 25%
• Neoplastic Disorders 12%
• Open-label Trial 100%
• Positive Symptoms 25%
• Primary Outcome Measure 12%
• Retinoids 12%
• Safe Medication 12%
• Schizophrenia 12%
• Schizophrenia Treatment 12%
• Schizophrenic Patients 100%
• Serum Levels 12%
• Study Support 12%
• Symptom Scale 37%
• Symptom Score 25%
• Synthetic Retinoid 12%
• Thyroid Function 12%
• Triglycerides 12%

Medicine and Dentistry

• Abnormal Involuntary Movement Scale 12%
• Barnes Akathisia Scale 12%
• Bexarotene 100%
• Blood Cell 12%
• Cell Count 12%
• Dermatological Agent 12%
• Disease 12%
• Drug Therapy 12%
• Extrapyramidal Symptoms 25%
• Laboratory Test 12%
• Liver Function 12%
• Low Drug Dose 25%
• Mental Health 25%
• Open-Label Trial 100%
• Positive and Negative Syndrome Scale 25%
• Rating Scale 25%
• Retinoid 25%
• Symptom 12%
• Thyroid Function 12%
• Treatment of Schizophrenia 12%
• Triacylglycerol 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Akathisia 12%
• Antipsychotic 100%
• Bexarotene 100%
• Dermatological Agent 12%
• Disease 12%
• Dyskinesia 12%
• Extrapyramidal Symptoms 25%
• Negative Syndrome 25%
• Open-Label Trial 100%
• Positive Syndrome 25%
• Retinoid 25%
• Schizophrenia 25%
• Symptom 12%
• Triacylglycerol 12%